FrancophonIA/ELRC3.0 huggingface dataset:
English: In a study involving 74 adults and adolescents aged 13 or above, 29 patients given Refixia as a weekly preventive treatment had around 1 bleeding episode a year, and 15 patients given Refixia for treating bleedings ‘on demand' had around 16 bleeding episodes a year.
Estonian: Uuringus, milles osales 74 täiskasvanut ja vähemalt 13-aastast noorukit, esines 29 patsiendil, kellele manustati Refixiat iganädalase ennetava ravina, ligikaudu 1 verejooksuepisood aastas ning 15 patsiendil, kellele manustati Refixiat verejooksude raviks vajaduse korral, esines ligikaudu 16 verejooksuepisoodi aastas.
English: Refixia must not be used in patients allergic to hamster proteins.
Estonian: Samuti ei tohi Refixiat kasutada hamstri valkude suhtes allergilised patsiendid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Refixia have been included in the summary of product characteristics and the package leaflet.
Estonian: Refixia ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This is a summary of the European public assessment report (EPAR) for Refixia.
Estonian: See on ravimi Refixia Euroopa avaliku hindamisaruande kokkuvõte.
English: What are the risks associated with Refixia?
Estonian: Mis riskid Refixiaga kaasnevad?
English: Studies show that Refixia is effective at preventing and treating bleeding episodes in patients with haemophilia B and its safety is comparable to that of other factor IX products.
Estonian: Uuringud tõendavad, et Refixia on efektiivne verejooksuepisoodide ennetamisel ja ravis B-hemofiiliaga patsientidel ning selle ohutus on võrreldav teiste IX hüübimisfaktori preparaatide ohutusega.
English: It replaces the missing factor IX, thereby helping the blood to clot and giving temporary control of bleeding.
Estonian: See asendab puuduvat IX hüübimisfaktorit, aidates verel hüübida ja verejooksu ajutiselt peatada.
English: Refixia nonacog beta pegol
Estonian: Refixia beetanonakogpegool
English: The company that markets Refixia will conduct a study to investigate the potential effects of PEG accumulation in the choroid plexus of the brain and other organs.
Estonian: Refixia turustaja korraldab uuringu, milles jälgib PEG peaaju soonepõimikus ja muudes elundites ladestumise võimalikku mõju.
English: For practical information about using Refixia, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Refixia kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: 87% of bleeding episodes resolved with one injection of Refixia.
Estonian: 87% verejooksuepisoodidest lahenes Refixia ainsa süstiga.
English: Some patients taking factor IX medicines may develop inhibitors (antibodies) against factor IX, causing the medicine to stop working and resulting in a loss of bleeding control.
Estonian: Mõnel IX hüübimisfaktorit sisaldavaid ravimeid võtval patsiendil võivad tekkida IX hüübimisfaktori vastased inhibiitorid (antikehad), mis peatavad ravimi toime, nii et see enam ei peata verejookse.
English: What benefits of Refixia have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Refixia kasulikkus?
English: Refixia contains the active substance nonacog beta pegol.
Estonian: Refixia sisaldab toimeainena beetanonakogpegooli.
English: The active substance in Refixia, nonacog beta pegol, works in the body in the same way as human factor IX.
Estonian: Refixia toimeaine beetanonakogpegool toimib organismis samamoodi nagu inimese IX hüübimisfaktor.
English: Around 86% of bleeding episodes resolved with one injection.
Estonian: Ligikaudu 86% verejooksuepisoodidest lahenes Refixia ainsa süstiga.
English: How is Refixia used?
Estonian: Kuidas Refixiat kasutatakse?
English: Refixia has been shown to be effective at both treating bleeding episodes and keeping the number of episodes low.
Estonian: Refixia on osutunud efektiivseks verejooksuepisoodide ravis ja nende arvu vähendamisel.
English: For more information about treatment with Refixia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Refixiaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Patients had around 1 bleeding episode per year and Refixia was rated excellent or good at treating around 93% of bleeding episodes.
Estonian: Nendel patsientidel esines ligikaudu 1 verejooksuepisood aastas ja episoodidest ligikaudu 93% korral hinnati Refixia ravitoime suurepäraseks või heaks.
English: However, part of the active substance in Refixia (called PEG) may accumulate in the body, including in a structure in the brain called choroid plexus, following long-term treatment.
Estonian: Refixia toimeaine teatud osa (PEG) võib aga pikaajalisel ravil hakata organismis ladestuma, sealhulgas peaaju soonepõimikus.
English: For further information on how to use this medicine, see the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave Refixia kasutamise kohta on ravimi omaduste kokkuvõttes (mis on samuti Euroopa avaliku hindamisaruande osa).
English: In addition, when bleeding did occur, Refixia was rated excellent or good at treating around 92% of bleeding episodes.
Estonian: Verejooksu esinemisel hinnati Refixia ravitoime ligikaudu 92% verejooksu episoodide korral suurepäraseks või heaks.
English: Patients with haemophilia B lack factor IX, a protein needed for normal clotting of the blood, and as a result, they bleed readily.
Estonian: B-hemofiiliaga patsientidel puudub IX hüübimisfaktor, mis on vere normaalseks hüübimiseks vajalik valk.
English: Refixia is a medicine used to treat and prevent bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of a clotting protein called factor IX.
Estonian: Refixia on ravim, mida kasutatakse verejooksude raviks ja ennetamiseks patsientidel, kellel on Bhemofiilia (IX hüübimisfaktori vaegusest tingitud pärilik hüübimishäire).
English: Factor IX medicines can also potentially cause problems due to the formation of blood clots in the blood vessels.
Estonian: IX hüübimisfaktorit sisaldavad ravimid võivad samuti põhjustada probleeme trombide (soonesiseste verehüüvete) tekke tõttu.
English: Refixia can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.
Estonian: Ravi peab toimuma hemofiilia ravis kogenud arsti järelevalve all.
English: How does Refixia work?
Estonian: Kuidas Refixia toimib?
English: This could mean that the treatment will not work properly.
Estonian: See võib tähendada, et ravi ei toimi õigesti.
English: Date of first authorisation: 16 March 2016
Estonian: Müügiloa esmase väljastamise kuupäev: 16. märts 2016
English: • The product is now ready for use.
Estonian: • Ravim on nüüd kasutamiseks valmis.
English: • If you are using this medicine for the first time, your doctor will supervise you
Estonian: • Kui kasutate seda ravimit esimest korda, juhendab arst teid
English: Your doctor will check regularly for the development of these antibodies, and especially before an operation.
Estonian: Teie arst kontrollib teid regulaarselt nende antikehade tekkimise suhtes ning eriti enne operatsiooni.
English: The dose and frequency should be based on the individual clinical response.
Estonian: Annus ja sagedus tuleb määrata individuaalse kliinilise reaktsiooni põhjal.
English: Check with your doctor if you think this applies to you.
Estonian: Küsige oma arstilt, kui arvate, et see kehtib ka teie suhtes.
English: Always consult your doctor before deciding to stop your treatment.
Estonian: Pidage alati nõu arstiga, enne kui otsustate ravi lõpetada.
English: <1/1,000) or very rare (<1/10,000) cannot be estimated from the available data.
Estonian: <1/1000) või väga harva (<1/10 000) esinevaid kõrvalnähte ei saa hinnata olemasolevate andmete alusel.
English: The listed warnings and precautions for adults also apply to children (aged 2 to 11 years) and adolescents (aged 12 to 18 years).
Estonian: Täiskasvanute kohta esitatud hoiatused ja ettevaatusabinõud on kohaldatavad ka lastele (vanuses 2 kuni 11 aastat) ja noorukitele (vanuses 12 kuni 18 aastat).
English: Repeat at intervals of 24 hours until the bleed stops.
Estonian: Korrata 24-tunniste intervallidega kuni verejooksu lõppemiseni.
English: If the solution is cloudy or has any particles, do not use it.
Estonian: Kui lahus on hägune või sisaldab osakesi, ärge seda kasutage.
English: Dissolving your medicines before use
Estonian: Ravimite lahustamine enne kasutamist
English: How much is given before, during and after major surgery?
Estonian: Millises koguses ravimit antakse enne olulist operatsiooni, selle ajal ja pärast seda?
English: Six children (66.7%) remained free of bleeds during routine prophylaxis.
Estonian: Kuus last (66,7%) püsis rutiinse profülaktika ajal verejooksudeta.
English: use after reconstitution.
Estonian: kasutamiseks pärast lahustamist.
English: Each pack contains:
Estonian: Üks pakend sisaldab:
English: For i.v.
Estonian: i.v.
English: The mean age was 7.3 (range 2.6 to 11.9) years.
Estonian: Keskmine vanus oli 7,3 (vahemikus 2,6 kuni 11,9) aastat.
English: Transmissible Agents
Estonian: Ülekanduvad agensid
English: In this situation, the appropriate dose would be:
Estonian: Sel juhul oleks sobiv annus järgmine:
English: How much is given regularly for long-term prevention of bleeds?
Estonian: Kui palju manustatakse regulaarselt verejooksude pikaajaliseks profülaktikaks?
English: Bio Products Laboratory Limited, Dagger Lane, Elstree, Hertfordshire, WD6 3BX, United Kingdom For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Estonian: Bio Products Laboratory Limited, Dagger Lane, Elstree, Hertfordshire, WD6 3BX, Ühendkuningriik Lisaküsimuste tekkimisel selle ravimi kohta pöörduge palun müügiloa hoidja kohaliku esindaja poole:
English: Your doctor will arrange for the appropriate laboratory tests to see if this is the case.
Estonian: Arst laseb teha vastavad laboratoorsed testid, et välja selgitada, kas põhjus on tõepoolest selles.
English: Frequency, type and severity of adverse reactions in children are expected to be the same as in adults (see section 5.1).
Estonian: Kõrvaltoimete esinemissagedus, tüüp ja raskusaste on lastel eeldatavalt sama kui täiskasvanutel (vt lõik 5.1).
English: The transfer device supplied with the product is sterile and cannot be used more than once.
Estonian: Preparaadiga kaasasolev ülekandeseade on steriilne ja seda ei saa mitu korda kasutada.
English: This also applies to any unknown or emerging viruses or other types of infections.
Estonian: Sama kehtib ka mis tahes teadmata või tekkivate viiruste või muud tüüpi infektsioonide kohta.
English: Depending on individual clinical response, longer intervals, e.g. once weekly, might be adequate (see section 5.1).
Estonian: Olenevalt individuaalsest kliinilisest ravivastusest võib piisata pikematest intervallidest, nt üks kord nädalas (vt lõik 5.1).
English: The median dosing interval for all of the nine children was 3 days (range 2 to 8 days).
Estonian: Mediaanne annustamisintervall oli kõigil üheksal lapsel kolm päeva (vahemikus 2 kuni 8 päeva).
English: After: During the first few days after the operation, your plasma factor X concentration will be checked regularly.
Estonian: Pärast: esimese paari päeva jooksul pärast operatsiooni kontrollitakse regulaarselt X faktori taset plasmas.
English: Virus safety
Estonian: Ohutus viiruste suhtes
English: However, chemical and physical in-use stability has been demonstrated for 1 hour at room temperature (up to 25°C +/-2°C).
Estonian: Ravimi kasutusaegne keemilis-füüsikaline stabiilsus on tõestatud 1 tunni jooksul toatemperatuuril (kuni 25°C ± 2°C).
English: Make sure you use the product within an hour after it has been made up.
Estonian: Kasutage ravimit kindlasti ühe tunni jooksul pärast valmistamist.
English: Four subjects were aged 0 to 5 years and five were aged 6 to 11 years inclusive.
Estonian: Neli uuringus osalejat olid 0- kuni 5-aastased ja viis 6- kuni 11-aastased.
English: 70 x (90-15) x 0.5 = 2,625 IU.
Estonian: 70 × (90-15) × 0,5 = 2625 RÜ.
English: These include:
Estonian: Sisaldab ka:
English: Ninety eight (53%) were major bleeding episodes, and 88 (47%) were minor bleeds (one bleed was not assessed).
Estonian: 98 (53%) olid olulised veritsemisepisoodid ja 88 (47%) olid vähem tähtsad veritsemised (ühte verejooksu ei hinnatud).
English: Before injecting this medicine at home, you should have received training by your healthcare professional on how to do so.
Estonian: Enne selle ravimi kodus süstimist peate olema saanud oma tervishoiutöötajalt vastava väljaõppe.
English: Your doctor will recommend an appropriate dose for you.
Estonian: Arst soovitab teile sobivat annust.
English: Your doctor will explain to you how much you should use, when you should use it and for how long.
Estonian: Arst selgitab teile, millises koguses, millal ja kui kaua seda ravimit kasutada.
English: During the dose-adjustment phase, two trough levels were <5 IU/dL but thereafter none were below this threshold.
Estonian: Annuse kohandamise etapil olid kaks minimaalset taset < 5 RÜ/dl, kuid seejärel ükski alla selle läve ei langenud.
English: The dose you need will be calculated by your doctor.
Estonian: Vajaliku annuse arvutab välja teie arst.
English: Generally the doses for children less than 12 years old are larger than doses for adolescents which should follow those in adults.
Estonian: Üldiselt on alla 12-aastaste laste annused suuremad kui noorukite annused, mis peaksid olema sarnased täiskasvanute annustega.
English: The careful control of dose and duration of treatment is especially important in cases of major surgery.
Estonian: Annuse ja ravi kestuse hoolikas kontrollimine on eriti olulised suurte operatsioonide korral.
English: Once made up, Coagadex must be used within one hour.
Estonian: Valmistatud Coagadex'i lahus tuleb kasutada ühe tunni jooksul.
English: - if the dissolved powder and solvent form a gel or a clot (if this happens please tell your healthcare provider, reporting the batch number printed on the vial).
Estonian: - Kui lahustunud pulber ja lahusti moodustavad geeli või klombi (kui nii juhtub, teavitage tervishoiuteenuse pakkujat, esitades viaalile trükitud partii numbri).
English: Frequencies of uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Estonian: Aeg-ajalt (≥1/1000 kuni <1/100); harva (≥1/10 000 kuni
English: Your doctor will advise if this use is suitable for you and, if so, of the appropriate dose.
Estonian: Teie arst annab teile nõu, kas selline kasutamine teile sobib ja milline on sel juhul sobiv annus.
English: In case of shock, the current medical standards for shock treatment should be observed.
Estonian: Šoki korral tuleb järgida šoki ravile kehtivaid standardseid juhiseid.
English: Both before and after treatment with this medicine, particularly for your first course of treatment, your doctor will probably carry out tests to check the level of factor X in your blood.
Estonian: Nii enne kui ka pärast ravi selle ravimiga, eriti teie esimeseks ravikuuriks, teeb arst analüüsid, mis näitavad X faktori taset teie veres.
English: Three children (33.3%), one in the 0-5 years age group and two in the 6-11 years age group had a total of 10 bleeds due to epistaxes, trauma or menorrhagia.
Estonian: Kolmel lapsel (33,3%), neist ühel 0-5 aasta vanuserühmas ja kahel 6-11 aasta vanuserühmas, oli kokku 10 verejooksu, mida põhjustas ninaverejooks, trauma või menorraagia.
English: In general, all patients treated with Coagadex should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
Estonian: Üldiselt tuleb kõiki Coagadex'iga ravitavaid patsiente hoolikalt jälgida, tehes inhibiitorite tekke tuvastamiseks vastavaid kliinilisi vaatlusi ja laboratoorseid teste.
English: Coagadex has no or negligible influence on the ability to drive and use machines.
Estonian: Coagadexil ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
English: Your treatment centre will provide a special container to dispose of any solution that remains, any used syringes, needles and empty containers.
Estonian: Raviasutus annab teile spetsiaalse mahuti mis tahes järelejäänud lahuse, kasutatud süstalde, nõelte ja tühjade mahutite äraviskamiseks.
English: The third study evaluated the use of Coagadex in routine prophylaxis of bleeding episodes in nine children aged less than 12 years of age.
Estonian: Kolmandas uuringus hinnati Coagadex'i kasutamist verejooksuepisoodide rutiinseks profülaktikaks üheksal alla 12-aastasel lapsel.
English: 70 kg x 90 IU/dL/{[2 IU/dL]/[IU/kg]} = 3150 IU.
Estonian: 70 kg × 90 RÜ/dl / {[2 RÜ/dl] / [RÜ/kg]} = 3150 RÜ.
English: Contents of the pack and other information What Coagadex contains
Estonian: Pakendi sisu ja muu teave Mida Coagadex sisaldab
English: Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes.
Estonian: Asendusravi hoolikas kontrollimine on eriti oluline suurte operatsioonide või eluohtlike verejooksuepisoodide korral.
English: Although the dose can be estimated using the calculations above, whenever possible appropriate laboratory tests, such as serial factor X assays, should be performed to guide dose adjustments.
Estonian: Kuigi annust saab eespool toodud arvutuste abil hinnata, tuleb võimaluse korral alati teha sobivad laboratoorsed testid, nagu X faktori saritestid, mis aitavad annust kohandada.
English: Paediatric population (less than 12 years of age)
Estonian: Lapsed (alla 12 aasta vanused)
English: - If you have any further questions, ask your doctor.
Estonian: - Kui teil on lisaküsimusi, pidage nõu oma arsti.
English: Of the 187 bleeding episodes in the efficacy analysis, 155 bleeds (83%) were treated with one infusion, 28 bleeds (15%) with two infusions, 3 bleeds (2%) with three infusions and 1 bleed (0.5%) with four infusions.
Estonian: Efektiivsuse analüüsiga hõlmatud 187 veritsemisepisoodist raviti 155 (83%) ühe infusiooniga, 28 veritsemist (15%) kahe infusiooniga, 3 veritsemist (2%) kolme infusiooniga ja üht veritsemist (0,5%) nelja infusiooniga.
English: -if you have a larger or longer bleed than usual and the bleeding does not stop after an injection of Coagadex.
Estonian: - kui teil esineb tavalisest suuremaid või kauem kestvaid verejookse ning kui verejooks ei lakka pärast Coagadex'i süsti.
English: Due to the rarity of hereditary factor X deficiency, experience regarding the use of Coagadex during pregnancy and breast-feeding is not available.
Estonian: Päriliku X faktori puudulikkuse harukordsuse tõttu ei ole andmeid Coagadex'i kasutamise kohta raseduse ja imetamise ajal.
English: The measures taken are considered effective for the following viruses: human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, hepatitis A virus and parvovirus B19.
Estonian: Kasutatavaid meetmeid loetakse efektiivseteks järgmiste viiruste suhtes: inimese immuunpuudulikkuse viirus (HIV), B-hepatiidi viirus, C-hepatiidi viirus, A-hepatiidi viirus ja parvoviirus B19.
English: sodium hydroxide and sucrose (see section 2 for further information about ingredients).
Estonian: naatriumhüdroksiid ja sahharoos (lisateavet koostisosade kohta vt lõik 2).
English: Allergic reactions (hypersensitivity reactions) have occurred rarely in the treatment of bleeding disorders with similar medicines (affecting up to 1 in 1,000 people), and sometimes progress to shock.
Estonian: Veritsemishäirete ravimisel sarnaste ravimitega on harva (kuni 1 inimesel 1000-st) esinenud allergilisi reaktsioone (ülitundlikkusreaktsioone), mis mõnikord arenevad šokiks.
English: For safety information with respect to transmissible agents, see section 4.4.
Estonian: Ohutusalast teavet nakkusekandjate kohta vt lõik 4.4.
English: Transfer Device (Mix2Vial).
Estonian: Ülekandeseade (Mix2Vial).
English: Four bleeding episodes in two subjects were considered treatment failures.
Estonian: Nelja veritsemisepisoodi kahel uuringus osalejal ravida ei õnnestunud.
English: Some patients may achieve desired FX trough levels on once weekly prophylactic therapy (see section 5.1).
Estonian: Mõnel patsiendil võidakse soovitud minimaalsed X faktori tasemed saavutada üks kord nädalas manustatava profülaktilise raviga (vt lõik 5.1).
English: Your treatment should be initiated by a doctor who is experienced in the treatment of bleeding disorders.
Estonian: Teie ravi peab alustama veritsemishäirete ravis kogenud arst.
English: One subject, aged 58 years, used 28 IU/kg once weekly for 8 weeks and, later, 25 IU/kg every 2 weeks for more than 5 months.
Estonian: Ühel 58-aastasel uuringus osalejal kasutati 28 RÜ/kg üks kord nädalas 8 nädala jooksul ja edaspidi 25 RÜ/kg iga 2 nädala järel rohkem kui 5 kuu jooksul.
English: • Each individual bleed should be judged on its own severity
Estonian: • Iga verejooksu tuleb hinnata eraldi selle raskusastme põhjal
English: For home therapy, the patient should be given appropriate training and reviewed at intervals.
Estonian: Koduseks raviks tuleb patsiendile teha vastav väljaõpe ja seda regulaarselt korrata.
English: • The injection should be repeated as necessary to stop the bleeding
Estonian: • Verejooksu peatamiseks tuleb süstimist vajadusel korrata
English: Frequencies have been evaluated according to the following convention: very common (≥1/10 subjects); common (≥1/100 to <1/10).
Estonian: Esinemissagedust on hinnatud järgmise konventsiooni kohaselt: väga sage (≥1/10 patsienti); sage (≥1/100 kuni <1/10).
English: Follow the normal safety practices for administration.
Estonian: Järgige manustamisel tavapärast ohutustehnikat.
English: Your doctor will usually tell you your dose in terms of the number of full vials that supply the dose most suited to you.
Estonian: Tavaliselt määrab arst annuseks teatud arvu täisviaale, mis annab teile sobivaima annuse.
English: The other subject, aged 22 years, used 24.6 IU/kg once weekly for 8.5 months.
Estonian: Teisel, 22-aastasel uuringus osalejal kasutati 24,6 RÜ/kg üks kord nädalas 8,5 kuu vältel.
English: When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to recipients.
Estonian: Inimese verest või plasmast tehtud ravimite puhul kasutatakse teatud meetmeid, et ennetada infektsioonide ülekandumist ravimi saajatele.
English: The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped viruses HAV and parvovirus B19.
Estonian: Võetud meetmeid loetakse efektiivseteks kestaga viiruste, nt HIV, HBV ja HCV, ning kestata viiruste HAV ja parvoviirus B19 suhtes.
English: Other medicines and Coagadex
Estonian: Muud ravimid ja Coagadex
English: The dose and duration of the treatment depend on the severity of the factor X deficiency (i.e. the patient's baseline factor X level), on the location and extent of the bleeding and on the patient's clinical condition.
Estonian: Annus ja ravi kestus olenevad X faktori puudulikkuse raskusastmest (s.t patsiendi X faktori tasemest esimesel visiidil), verejooksu asukohast ja ulatusest ning patsiendi kliinilisest seisundist.
English: For all surgical procedures, Coagadex was assessed as excellent (no post-operative bleeding, no requirement of blood transfusions, and blood loss was no more than ‘as expected') in controlling blood loss during and after surgery.
Estonian: Kõikide kirurgiliste protseduuride puhul hinnati Coagadex verekaotuse piiramisel operatsiooni ajal ja järel väga heaks (puudus operatsioonijärgne veritsemine, ei vajatud vereülekandeid ning verekaotus ei olnud eeldatust suurem).